Exozymes (EXOZ) Competitors $16.91 +0.01 (+0.06%) As of 03/3/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends EXOZ vs. TRDA, ARCT, PRTC, KROS, SAGE, STOK, CDXC, HUMA, SNDL, and ALLOShould you be buying Exozymes stock or one of its competitors? The main competitors of Exozymes include Entrada Therapeutics (TRDA), Arcturus Therapeutics (ARCT), PureTech Health (PRTC), Keros Therapeutics (KROS), Sage Therapeutics (SAGE), Stoke Therapeutics (STOK), ChromaDex (CDXC), Humacyte (HUMA), SNDL (SNDL), and Allogene Therapeutics (ALLO). These companies are all part of the "pharmaceutical products" industry. Exozymes vs. Entrada Therapeutics Arcturus Therapeutics PureTech Health Keros Therapeutics Sage Therapeutics Stoke Therapeutics ChromaDex Humacyte SNDL Allogene Therapeutics Exozymes (NASDAQ:EXOZ) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership. Which has preferable earnings and valuation, EXOZ or TRDA? Exozymes has higher earnings, but lower revenue than Entrada Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExozymesN/AN/AN/AN/AN/AEntrada Therapeutics$210.78M2.01-$6.68M$1.915.93 Do analysts prefer EXOZ or TRDA? Entrada Therapeutics has a consensus target price of $25.67, indicating a potential upside of 126.54%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Entrada Therapeutics is more favorable than Exozymes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exozymes 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Do institutionals & insiders hold more shares of EXOZ or TRDA? 86.4% of Entrada Therapeutics shares are owned by institutional investors. 7.6% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer EXOZ or TRDA? Entrada Therapeutics received 20 more outperform votes than Exozymes when rated by MarketBeat users. CompanyUnderperformOutperformExozymesN/AN/AEntrada TherapeuticsOutperform Votes2083.33% Underperform Votes416.67% Is EXOZ or TRDA more profitable? Entrada Therapeutics has a net margin of 25.53% compared to Exozymes' net margin of 0.00%. Entrada Therapeutics' return on equity of 16.11% beat Exozymes' return on equity.Company Net Margins Return on Equity Return on Assets ExozymesN/A N/A N/A Entrada Therapeutics 25.53%16.11%10.39% Does the media favor EXOZ or TRDA? In the previous week, Entrada Therapeutics had 14 more articles in the media than Exozymes. MarketBeat recorded 15 mentions for Entrada Therapeutics and 1 mentions for Exozymes. Exozymes' average media sentiment score of 1.87 beat Entrada Therapeutics' score of 0.63 indicating that Exozymes is being referred to more favorably in the media. Company Overall Sentiment Exozymes Very Positive Entrada Therapeutics Positive SummaryEntrada Therapeutics beats Exozymes on 12 of the 13 factors compared between the two stocks. Get Exozymes News Delivered to You Automatically Sign up to receive the latest news and ratings for EXOZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXOZ vs. The Competition Export to ExcelMetricExozymesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.72M$3.08B$5.81B$8.40BDividend YieldN/A1.51%4.75%3.98%P/E RatioN/A28.6624.9519.25Price / SalesN/A403.87375.55110.22Price / CashN/A168.6838.0534.58Price / BookN/A3.487.334.28Net IncomeN/A-$71.55M$3.18B$247.04M7 Day Performance-3.54%-5.00%-2.87%-3.25%1 Month PerformanceN/A-10.68%-6.77%-6.55%1 Year PerformanceN/A-22.37%12.32%4.01% Exozymes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXOZExozymesN/A$16.91+0.1%N/AN/A$105.72MN/A0.0029Positive NewsGap UpTRDAEntrada Therapeutics3.1516 of 5 stars$12.02-0.8%$25.67+113.5%-17.5%$449.79M$215.23M7.56110Earnings ReportAnalyst RevisionARCTArcturus Therapeutics2.7524 of 5 stars$16.58+3.2%$65.00+292.1%-60.5%$449.13M$169.93M-7.47180Upcoming EarningsPRTCPureTech Health1.8592 of 5 stars$18.58+2.1%$45.00+142.2%-31.7%$444.84M$3.33M0.00100Gap UpKROSKeros Therapeutics3.3478 of 5 stars$10.94+0.4%$52.56+380.4%-83.9%$443.15M$651,000.00-2.10100Earnings ReportAnalyst RevisionNews CoverageSAGESage Therapeutics3.8646 of 5 stars$7.17-2.3%$9.65+34.5%-67.1%$440.82M$41.24M-1.09690STOKStoke Therapeutics3.7698 of 5 stars$8.27+0.2%$23.00+178.1%-3.0%$438.04M$16.74M-3.94100Positive NewsCDXCChromaDex4.252 of 5 stars$5.66+4.0%$8.00+41.3%+241.6%$432.33M$91.67M566.57120HUMAHumacyte2.4186 of 5 stars$3.43+12.8%$13.71+299.8%-5.6%$431.70M$1.57M-2.56150High Trading VolumeSNDLSNDL3.7916 of 5 stars$1.63+0.6%$3.25+99.4%+13.0%$428.33M$911.22M-5.262,516ALLOAllogene Therapeutics2.819 of 5 stars$2.04+2.8%$9.95+387.7%-63.6%$427.73M$90,000.00-1.31310Gap Down Related Companies and Tools Related Companies Entrada Therapeutics Competitors Arcturus Therapeutics Competitors PureTech Health Competitors Keros Therapeutics Competitors Sage Therapeutics Competitors Stoke Therapeutics Competitors ChromaDex Competitors Humacyte Competitors SNDL Competitors Allogene Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EXOZ) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exozymes Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exozymes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
